Current methods for the synthesis of homogeneous antibody-drug conjugates

Biotechnology Advances

Volumn 33, Issue 6, 2015, Pages 775-784

  Sochaj, Alicja M ^a   Świderska, Karolina W ^a   Otlewski, Jacek ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

ADCs; Cytotoxic agents; Homogeneity; Monoclonal antibodies; Site specific conjugation; Targeted cancer therapy

Indexed keywords

AMINO ACIDS; DISEASES; MONOCLONAL ANTIBODIES; ONCOLOGY;

ADCS; CYTOTOXIC AGENTS; HOMOGENEITY; SITE-SPECIFIC; TARGETED CANCER THERAPY;

ANTIBODIES;

AMINO ACID; ANTIBODY; ANTIGEN; BIOTECHNOLOGY; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG; EFFICIENCY MEASUREMENT; ENZYME ACTIVITY; HOMOGENEITY; TUMOR;

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL; BIOTECHNOLOGY; DRUG DELIVERY SYSTEM; HUMAN; MOUSE; NEOPLASMS; PROCEDURES; PROTEIN ENGINEERING; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; MICE; NEOPLASMS; PROTEIN ENGINEERING; RATS;

EID: 84939263374     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.05.001     Document Type: Review

References (83)

1. Agarwal P., Bertozzi C.R. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug. Chem. 2015, 26:176-192.
2. Agarwal P., Kudirka R., Albers A.E., Barfield R.M., de Hart G.W., Drake P.M., Jones L.C., Rabuka D. Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug. Chem. 2013, 24:846-851.
3. Alley S.C., Benjamin D.R., Jeffrey S.C., Okeley N.M., Meyer D.L., Sanderson R.J., Senter P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 2008, 19:759-765.
4. Alvarenga L., Zahid M., Tommaso A., Juste M., Aubrey N., Billiald P., Muzard J. Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential. Toxins (Basel) 2014, 6:2541-2567.
5. Andersen D.C., Reilly D.E. Production technologies for monoclonal antibodies and their fragments. Curr. Opin. Biotechnol. 2004, 15:456-462.
6. Axup J.Y., Bajjuri K.M., Ritland M., Hutchins B.M., Kim C.H., Kazane S.A., Halder R., Forsyth J.S., Santidrian A.F., Stafin K., et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. 2012, 109:16101-16106.
7. Badescu G., Bryant P., Bird M., Henseleit K., Swierkosz J., Parekh V., Tommasi R., Pawlisz E., Jurlewicz K., Farys M., et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug. Chem. 2014, 25:1124-1136.
8. Barginear M.F., John V., Budman D.R. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol. Med. 2012, 18:1473-1479.
9. Behrens C.R., Liu B. Methods for site-specific drug conjugation to antibodies. MAbs 2014, 6:46-53.
10. Bodet-Milin C. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Front. Oncol. 2013, 3:1-13.
11. Boeggeman E., Ramakrishnan B., Pasek M., Manzoni M., Puri A., Loomis K.H., Waybright T.J., Qasba P.K. Site specific conjugation of fluoroprobes to the remodeled Fc N-Glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. Bioconjug. Chem. 2009, 20:1228-1236.
12. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., Pazdur R. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7:1490-1496.
13. Cal P.M.S.D., Bernardes G.J.L., Gois P.M.P. Cysteine-selective reactions for antibody conjugation. Angew. Chem. Int. Ed. Engl. 2014, 53:10585-10587.
14. Chamarthy M.R., Williams S.C., Moadel R.M. Radioimmunotherapy of non-Hodgkin's lymphoma: from the "magic bullets" to "radioactive magic bullets". Yale J. Biol. Med. 2011, 84:391-407.
15. Cortez-Retamozo V., Backmann N., Senter P.D., Wernery U., De Baetselier P., Muyldermans S., Revets H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004, 64:2853-2857.
16. De Meyer T., Muyldermans S., Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 2014, 32:263-270.
17. Del Rosario R.B., Wahl R.L., Brocchini S.J., Lawton R.G., Smith R.H. Sulfhydryl site-specific crosslinking and labeling of monoclonal antibodies by a fluorescent equilibrium transfer alkylation crosslink reagent. Bioconjug. Chem. 1990, 1:51-59.
18. Dennler P., Chiotellis A., Fischer E., Brégeon D., Belmant C., Gauthier L., Lhospice F., Romagne F., Schibli R. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug. Chem. 2014, 25:569-578.
19. Doronina S.O., Toki B.E., Torgov M.Y., Mendelsohn B.A., Cerveny C.G., Chace D.F., DeBlanc R.L., Gearing R.P., Bovee T.D., Siegall C.B., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21:778-784.
20. Drake P.M., Albers A.E., Baker J., Banas S., Barfield R.M., Bhat A.S., de Hart G.W., Garofalo A.W., Holder P., Jones L.C., et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug. Chem. 2014, 25:1331-1341.
21. Eriksson S.E., Ohlsson T., Nilsson R., Tennvall J. Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model. Cancer Biother. Radiopharm. 2012, 27:175-182.
22. Eriksson S.E., Elgström E., Bäck T., Ohlsson T., Jensen H., Nilsson R., Lindegren S., Tennvall J. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model. Cancer Biother. Radiopharm. 2014, 29:238-246.
23. Francisco J.A., Cerveny C.G., Meyer D.L., Mixan B.J., Klussman K., Chace D.F., Rejniak S.X., Gordon K.A., DeBlanc R., Toki B.E., et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102:1458-1465.
24. Gaertner H.F., Offord R.E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug. Chem. 1996, 7:38-44.
25. Garber K. Bispecific antibodies rise again. Nat. Rev. Drug Discov. 2014, 13:799-801.
26. Geoghegan K.F., Stroh J.G. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. Bioconjug. Chem. 1992, 3:138-146.
27. Griffin M., Casadio R., Bergamini C.M. Transglutaminases: nature's biological glues. Biochem. J. 2002, 396:377-396.
28. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M.C., Lenox J., Cerveny C.G., Kissler K.M., Bernhardt S.X., Kopcha A.K., Zabinski R.F., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 2004, 10:7063-7070.
29. Hofer T., Skeffington L.R., Chapman C.M., Rader C. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 2009, 48:12047-12057.
30. Hui J.Z., Tsourkas A. Optimization of photoactive protein z for fast and efficient site-specific conjugation of native IgG. Bioconjug. Chem. 2014, 25:1709-1719.
31. Hui J.Z., Al Zaki A., Cheng Z., Popik V., Zhang H., Luning Prak E.T., Tsourkas A. Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticles. Small 2014, 10:3354-3363.
32. Jackson D., Atkinson J., Guevara C.I., Zhang C., Kery V., Moon S.J., Virata C., Yang P., Lowe C., Pinkstaff J., et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS One 2014, 9:e83865.
33. Jeger S., Zimmermann K., Blanc A., Grünberg J., Honer M., Hunziker P., Struthers H., Schibli R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. 2010, 49:9995-9997.
34. Johansson L., Gafvelin G., Arnér E.S.J. Selenocysteine in proteins - properties and biotechnological use. Biochim. Biophys. Acta 2005, 1726:1-13.
35. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y., Simpson M., Tsai S.P., Dennis M.S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 2008, 26:925-932.
36. Junutula J.R., Bhakta S., Raab H., Ervin K.E., Eigenbrot C., Vandlen R., Scheller R.H., Lowman H.B. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 2008, 332:41-52.
37. Junutula J.R., Flagella K.M., Graham R.A., Parsons K.L., Ha E., Raab H., Bhakta S., Nguyen T., Dugger D.L., Li G., et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res. 2010, 16:4769-4778.
38. Kim K.M., McDonagh C.F., Westendorf L., Brown L.L., Sussman D., Feist T., Lyon R., Alley S.C., Okeley N.M., Zhang X., et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol. Cancer Ther. 2008, 7:2486-2497.
39. Kim C.H., Axup J.Y., Schultz P.G. Protein conjugation with genetically encoded unnatural amino acids. Curr. Opin. Chem. Biol. 2013, 17:412-419.
40. Kim M.T., Chen Y., Marhoul J., Jacobson F. Statistical modeling of the drug load distribution on trastuzumab emtansine (kadcyla), a lysine-linked antibody drug conjugate. Bioconjug. Chem. 2014, 25:1223-1232.
41. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
42. Kryukov G.V., Castellano S., Novoselov S.V., Lobanov A.V., Zehtab O., Guigó R., Gladyshev V.N. Characterization of mammalian selenoproteomes. Science 2003, 300:1439-1443.
43. Lameris R., de Bruin R.C.G., Schneiders F.L., van Bergen en Henegouwen P.M.P., Verheul H.M.W., de Gruijl T.D., van der Vliet H.J. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 2014, 92:153-165.
44. Lemke E.A. The exploding genetic code. ChemBioChem 2014, 15:1691-1694.
45. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blättler W.A., Lambert J.M., Chari R.V.J., Lutz R.J., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280-9290.
46. Li X., Yang J., Rader C. Antibody conjugation via one and two C-terminal selenocysteines. Methods 2014, 65:133-138.
47. Liu H., May K. Structural variations, chemical modifications and possible impacts to stability and biological function disulfide bond structures of IgG molecules. MAbs 2012, 4:17-23.
48. LoRusso P.M., Weiss D., Guardino E., Girish S., Sliwkowski M.X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 2011, 17:6437-6447.
49. Maruani A., Smith M.E.B., Miranda E., Chester K.A., Chudasama V., Caddick S. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat. Commun. 2015, 6:6645.
50. McDonagh C.F., Turcott E., Westendorf L., Webster J.B., Alley S.C., Kim K., Andreyka J., Stone I., Hamblett K.J., Francisco J.A., et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 2006, 19:299-307.
51. Mercer N., Ramakrishnan B., Boeggeman E., Verdi L., Qasba P.K. Use of novel mutant galactosyltransferase for the bioconjugation of terminal N-Acetylglucosamine (GlcNAc) residues on live cell surface. Bioconjug. Chem. 2013, 24:144-152.
52. Nelson A.L. Antibody fragments: Hope and hype. MAbs 2010, 2:77-83.
53. Nilsson B., Moks T., Jansson B., Abrahmsén L., Elmblad A., Holmgren E., Henrichson C., Jones T.A., Uhlén M. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987, 1:107-113.
54. Panowksi S., Bhakta S., Raab H., Polakis P., Junutula J.R. Site-specific antibody drug conjugates for cancer therapy. MAbs 2014, 6:34-45.
55. Peddi P.F., Hurvitz S.A. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013, 9:319-326.
56. Perez H.L., Cardarelli P.M., Deshpande S., Gangwar S., Schroeder G.M., Vite G.D., Borzilleri R.M. Antibody-drug conjugates: Current status and future directions. Drug Discov. Today 2014, 19:869-881.
57. Perrino E., Steiner M., Krall N., Bernardes G.J.L., Pretto F., Casi G., Neri D. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 2014, 74:2569-2578.
58. Pro B., Advani R., Brice P., Bartlett N.L., Rosenblatt J.D., Illidge T., Matous J., Ramchandren R., Fanale M., Connors J.M., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 2012, 30:2190-2196.
59. Rabuka D., Rush J.S., deHart G.W., Wu P., Bertozzi C.R. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 2012, 7:1052-1067.
60. Ramakrishnan B., Qasba P.K. Structure-based design of β1,4-Galactosyltransferase I (β4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens β4Gal-T1 donor specificity. J. Biol. Chem. 2002, 277:20833-20839.
61. Ricart A.D. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin. Cancer Res. 2011, 17:6417-6427.
62. Romans D.G., Tilley C.A., Crookston M.C., Falk R.E., Dorrington K.J. Conversion of incomplete antibodies to direct agglutinins by mild reduction: evidence for segmental flexibility within the Fc fragment of immunoglobulin G. Proc. Natl. Acad. Sci. 1977, 74:2531-2535.
63. Schroeder D.D., Tankersly D.L., Lundblad J.L. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction. Vox Sang. 1981, 40:373-382.
64. Schumacher F.F., Nunes J.P.M., Maruani A., Chudasama V., Smith M.E.B., Chester K.A., Baker J.R., Caddick S. Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. Org. Biomol. Chem. 2014, 12:7261-7269.
65. Seegan G.W., Smith C.A., Schumaker V.N. Changes in quaternary structure of IgG upon reduction of the interheavy-chain disulfide bond. Proc. Natl. Acad. Sci. 1979, 76:907-911.
66. Senter P.D., Sievers E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30:631-637.
67. Shaunak S., Godwin A., Choi J.W., Balan S., Pedone E., Vijayarangam D., Heidelberger S., Teo I., Zloh M., Brocchini S. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat. Chem. Biol. 2006, 2:312-313.
68. Shen B.Q., Xu K., Liu L., Raab H., Bhakta S., Kenrick M., Parsons-Reponte K.L., Tien J., Yu S.F., Mai E., et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 2012, 30:184-189.
69. Spiess C., Zhai Q., Carter P.J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. 2015, (in press (available at http://www.sciencedirect.com/science/article/pii/S016158901500005X).
70. Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100years of progress. Nat. Rev. Cancer 2008, 8:473-480.
71. Strop P. Versatility of Microbial Transglutaminase. Bioconjug. Chem. 2014, 25:855-862.
72. Strop P., Liu S.H., Dorywalska M., Delaria K., Dushin R.G., Tran T.T., Ho W.H., Farias S., Casas M.G., Abdiche Y., et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 2013, 20:161-167.
73. Sun M.M.C., Beam K.S., Cerveny C.G., Hamblett K.J., Blackmore R.S., Torgov M.Y., Handley F.G.M., Ihle N.C., Senter P.D., Alley S.C. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 2005, 16:1282-1290.
74. Van de Donk N.W.C.J., Dhimolea E. Brentuximab vedotin. MAbs 2012, 4:458-465.
75. Wang L. Amersham Prize winner. Expanding the genetic code. Science 2003, 302:584-585.
76. Wang L., Brock A., Herberich B., Schultz P.G. Expanding the genetic code of Escherichia coli. Science 2001, 292:498-500.
77. Wang L., Amphlett G., Blättler W.A., Lambert J.M., Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 2005, 14:2436-2446.
78. Willner D., Trail P.A., Hofstead S.J., King H.D., Lasch S.J., Braslawsky G.R., Greenfield R.S., Kaneko T., Firestone R.A. (6-Maleimidocaproyl)hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 1993, 4:521-527.
79. Younes A., Gopal A.K., Smith S.E., Ansell S.M., Rosenblatt J.D., Savage K.J., Ramchandren R., Bartlett N.L., Cheson B.D., de Vos S., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J. Clin. Oncol. 2012, 30:2183-2189.
80. Zhou Q., Stefano J.E., Manning C., Kyazike J., Chen B., Gianolio D.A., Park A., Busch M., Bird J., Zheng X., et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug. Chem. 2014, 25:510-520.
81. Zhou Z., Zhang J., Sun L., Ma G., Su Z. Comparison of site-specific PEGylations of the N-terminus of interferon beta-1b: Selectivity, efficiency, and in vivo/vitro activity. Bioconjug. Chem. 2014, 25:138-146.
82. Zhu Z., Ramakrishnan B., Li J., Wang Y., Feng Y., Prabakaran P., Colantonio S., Dyba M.A., Qasba P.K., Dimitrov D.S. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs 2014, 6:1190-1200.
83. Zimmerman E.S., Heibeck T.H., Gill A., Li X., Murray C.J., Madlansacay M.R., Tran C., Uter N.T., Yin G., Rivers P.J., et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem. 2014, 25:351-361.